MindWalk Stock Earnings Estimates Decreased by HC Wainwright

MindWalk Holdings Corp. (NASDAQ:HYFT) – Equities researchers at HC Wainwright dropped their Q2 2027 EPS estimates for shares of MindWalk in a research note issued on Wednesday, September 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.05) for the quarter, down from their prior estimate of ($0.04). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for MindWalk’s Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.08) EPS, FY2027 earnings at ($0.28) EPS and FY2028 earnings at ($0.28) EPS.

Several other analysts also recently weighed in on HYFT. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. Finally, Zacks Research upgraded MindWalk from a “strong sell” rating to a “hold” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

MindWalk Trading Down 2.2%

MindWalk stock opened at $1.36 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.75 and a current ratio of 1.84. The business’s 50-day simple moving average is $1.35 and its 200-day simple moving average is $1.37. The firm has a market capitalization of $63.53 million, a PE ratio of -5.23 and a beta of 0.82. MindWalk has a 52 week low of $0.99 and a 52 week high of $2.99.

MindWalk (NASDAQ:HYFT) last released its earnings results on Monday, September 14th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%.The firm had revenue of $2.73 million for the quarter, compared to analyst estimates of $3.25 million.

Hedge Funds Weigh In On MindWalk

An institutional investor recently bought a new stake in MindWalk stock. BlackRock Inc. acquired a new stake in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned 0.33% of MindWalk at the end of the most recent quarter. Institutional investors own 6.70% of the company’s stock.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.